New treatment for advanced melanoma uses tumor to fight the disease

A new treatment for advanced melanoma, approved by the U.S. Food and Drug Administration (FDA), is offering renewed hope to patients. The therapy, known as tumor-infiltrating lymphocyte (TIL) therapy, harnesses the power of a patient's own tumor to fight the cancer.

This innovative approach involves extracting lymphocytes from a patient's tumor. These T-cells, which are immune cells that have already infiltrated the tumor, are then cultured and expanded in a laboratory. The expanded population of tumor-specific T-cells is then infused back into the patient, along with a regimen of chemotherapy and a drug to support the immune response.

The treatment represents a significant advancement in the fight against advanced melanoma, a form of skin cancer that can be particularly aggressive and difficult to treat. By leveraging the patient's own immune system, TIL therapy aims to provide a more targeted and potentially more effective treatment option for those with limited alternatives.